| Domestic Formulations | Branded pharmaceutical formulations targeting chronic and specialty therapies. | Strong brand equity, deep market penetration, and dedicated salesforce. | B2B and B2C customers including doctors and hospitals in India and Nepal. | Specialty and chronic therapy brands with life cycle management. | 42241 | 65 | Sales revenue from prescription drugs through domestic distribution and marketing. | Direct sales with focus on profitable product mix and brand building. | Launch of new specialty drugs, expanded customer coverage, and increasing prescription generation. | Azoran, Aldactone, Naprosyn, Seretane |
| International Formulations | Generic and branded generics oral solid formulations for global markets. | Manufacturing approvals from EU, Canada, Australia; strong supply chain partnerships. | Global generic drug buyers, distributors, and regulatory markets across Europe, Americas, Asia, and Africa. | Complex generics and low competition products requiring specialized manufacturing. | 13230 | 18 | Sales through exports and partnerships with global generic companies. | Contract sales and tenders in regulated and emerging markets. | Geographic expansion, regulatory approvals, new product registrations. | Azathioprine, Siloxogene, Dyzantil |
| Active Pharmaceutical Ingredients (API) | Manufacture and sale of APIs for internal use and external sales. | State-of-the-art manufacturing, quality certifications, and strategic integration with formulations. | Formulations divisions and pharmaceutical API buyers globally. | Specialty synthetic APIs used in immunosuppressants and niche therapies. | 9024 | 12 | Sales of bulk drugs and specialty APIs to formulations business and third parties. | Bulk sales and long-term supply contracts. | Backward integration, government API focus, customer expansion. | Quinfamide, Azathioprine, Haloperidol |
